TOP HAT, the UK trial testing the anti-sickness drug ondansetron against placebo for visual hallucinations in Parkinson's disease and dementia with Lewy bodies, is listed as recruiting on the ISRCTN register, with the date of final enrolment given as 31 July 2026. That entry was last edited on 13 November 2025. Recruitment had been stopped in 2024 on the advice of the trial's independent Data Monitoring and Ethics Committee: Parkinson's UK, which funds the study through its Virtual Biotech programme, said in a statement dated 22 April 2024 that the committee had reviewed data from the first 100 participants and judged that there were more safety issues in those given ondansetron than in those given placebo, and that participants then in the trial had been asked to stop their study drug while monitoring continued.
The design in the register is a double blind, individually randomised, placebo controlled, parallel group trial of flexibly dosed ondansetron at 8 to 24 mg a day, rising from one 8 mg tablet in weeks one and two to 24 mg a day by weeks five and six, with dose increases guided by telephone safety monitoring. The primary outcome is change in the Scale for Assessment of Positive Symptoms, hallucinations subscale, at 12 weeks, with follow up to 24 weeks and quetiapine available as rescue treatment for anyone whose symptoms remain distressing. Eligible participants are people with Parkinson's aged over 55 who have hallucinations at least weekly after other approaches, such as changing lighting or reducing Parkinson's medication, have failed; the entry criteria were later widened to include dementia with Lewy bodies. The companion ClinicalTrials.gov record, sponsored by University College London and last updated on 27 March 2024, gives a target of 306 participants and still shows the status as active and not recruiting, so the two registers do not currently agree.
What the committee saw has not been published. The monitored events listed by the funder included heart rate and rhythm, constipation and headache, and also falls, emergency department attendances, hospital admissions and deaths. Parkinson's UK has since said, in its account of the restart on its website, that the apparent imbalance was traced to data recording errors and that the team obtained regulatory approval to resume; neither register carries that explanation, and no analysis of the paused phase has appeared in a peer reviewed journal. The only published output using those early data is a methods paper in Psychological Medicine on 24 March 2025, which drew on blinded data from the first 100 Parkinson's participants, meaning no comparison between drug and placebo, to set the smallest change that would count as meaningful: a Delphi panel of 51 researchers and clinicians and 16 people with lived experience agreed on 2 points, on both the SAPS hallucinations subscale and the University of Miami Parkinson's Disease Hallucinations Questionnaire.
The premise of the trial is that current options are poor. The register's own summary notes that NHS treatment rests on antipsychotics, with quetiapine described as safer than the alternatives but of questionable effectiveness, clozapine as effective but impractical outside specialist units because of monitoring requirements, and pimavanserin as modest in effect, expensive and not licensed in the UK. Ondansetron is licensed in the UK as a short term anti-emetic, not for hallucinations, and the trial exists precisely because that question is unsettled. The registered enrolment date has now passed, and no register update recording the close of recruitment had been posted at the time of writing.